SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 17, 2005--Hana Biosciences (AMEX: HBX): Results confirm potential of Zensana(TM) (ondansetron oral spray) as the first oral spray 5-HT3 antagonist to deliver full doses of ondansetron faster and more conveniently than tablets. Pivotal clinical trials for 505(b)(2) registration to commence in December 2005. U.S. commercial launch targeted for 2007.
